APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
According to studies, 25-66% of patients with metastatic highly differentiated thyroid cancer (DTC) develop partial or complete resistance of metastases to therapy with radioactive iodine. The review discusses the molecular mechanisms for the involvement of various apoptosis proteins in the formatio...
Saved in:
Main Authors: | K.A. GARIPOV (Author), Z.A. AFANASIEVA (Author), A.D. GAFIULLINA (Author) |
---|---|
Format: | Book |
Published: |
Avicenna Tajik State Medical University,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018) -
Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022) -
Differentiated Thyroid Cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine Treatment
by: Costanza Chiapponi, et al.
Published: (2023) -
Effects of radioiodine therapy on fertility indicators among men with differentiated thyroid cancer: A cohort study
by: Salman Soltani, et al.
Published: (2023) -
That's not Metastatic Thyroid Cancer: Patterns of Non-malignant Radioiodine Uptake
by: Daniella F Pinho
Published: (2017)